Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Daewon Pharmaceutical Co., Ltd. for the period ending September 30, 2023. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
[기재정정]투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding a change in the terms of an M&A investment agreement for the acquisition of SD Biotechnologies. It details the consortium members, acquisition price, and payment structure, specifically noting a 'correction' (정정신고) to a previous filing. Since this document describes the details of an M&A transaction and its subsequent modification, it falls under the M&A Activity category.
2023-11-13 Korean
투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding the signing of an investment agreement for the acquisition of SD Biotechnologies by the DKS Consortium. It details the acquisition price, method (new shares and convertible bonds), and the legal status of the transaction. This falls under M&A activity (takeover/acquisition).
2023-11-13 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding the acquisition of shares in another company (SD Biotechnologies) through a third-party capital increase. This type of disclosure, involving M&A activity and strategic investment, falls under the category of M&A Activity (TAR).
2023-11-13 Korean
투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewon Pharmaceutical regarding the selection of the DKS Consortium as the final preferred bidder for the acquisition of SD Biotechnologies. It details the acquisition price, method (new share issuance and convertible bonds), and the legal context of the rehabilitation process. Since this document describes a specific merger and acquisition transaction, it falls under the M&A Activity category.
2023-10-05 Korean
금전대여결정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory disclosure regarding a 'Decision to Lend Money' (금전대여 결정) by Daewon Pharmaceutical to SD Biotechnologies. This type of disclosure, involving significant financial transactions or capital-related decisions, does not fit into specific categories like M&A, dividends, or director dealings. Therefore, it is classified as a general regulatory filing (RNS).
2023-09-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.